Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by canadafanon Jun 11, 2024 1:12pm

145 Views

Post# 36083066

Phase 2 questions

Casyl
yes the phase 2 trials were beyond successful, thst is why they have FDA fast track designation for the MBc & most importantly the PanCan & Now CGAR , $5 million grant to proceed.
in general terms, certainly not All phase 2 have been successful.
the Pancreatic cancer & MBc , yes 100%.
hence the request to meet with FDA to have various modifications to phase 3 based on previous trials & inclusions of biomarkers.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features